Benzinga
Benzinga
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Benzinga
jueves, octubre 22
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Camp4 Therapeutics Corp
CAMP
NASDAQ
Lista de seguimiento
Get Report
Trade with Public
Get Report
Trade with Public
$3.29
0.13
4.11%
Últ. Act.: Oct 21, 4:01 PM
$3.29
0.13
4.11%
Get Report
Panorámica general
Noticias
Previsión de beneficios
Eventos
Precios objetivo
Finanzas
Sentimiento
Propiedad
Comparar
Informe de acciones
Privacy Manager
Camp4 Therapeutics Financials
Camp4 Therapeutics (CAMP) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Camp4 Therapeutics Q2 EPS $(0.58) Misses $(0.21) Estimate, Sales $1.779M Miss $1.897M Estimate
Camp4 Therapeutics (NASDAQ:CAMP) reported quarterly losses of $(0.58) per share which missed the analyst consensus estimate of $(0.21) by 176.19 percent. This is a 6.45 percent increase over losses of $(0.62) per share
Benzinga Newsdesk
PRO
Camp4 Therapeutics Q1 EPS $(0.32) Misses $(0.29) Estimate, Sales $1.294M Beat $300.000K Estimate
Camp4 Therapeutics (NASDAQ:CAMP) reported quarterly losses of $(0.32) per share which missed the analyst consensus estimate of $(0.29) by 10.34 percent. This is a 48.39 percent increase over losses of $(0.62) per share
Benzinga Newsdesk
Camp4 Therapeutics Earnings Review: Q4 Summary
Benzinga Insights
PRO
Camp4 Therapeutics Q4 EPS $(0.87) Misses $(0.30) Estimate, Sales $348.000K Miss $538.000K Estimate
Camp4 Therapeutics (NASDAQ:CAMP) reported quarterly losses of $(0.87) per share which missed the analyst consensus estimate of $(0.30) by 190 percent. This is a 12.99 percent decrease over losses of $(0.77) per share
Benzinga Newsdesk
PRO
Camp4 Therapeutics Q3 EPS $(0.55) Beats $(0.68) Estimate, Sales $795.000K Beat $480.000K Estimate
Camp4 Therapeutics (NASDAQ:CAMP) reported quarterly losses of $(0.55) per share which beat the analyst consensus estimate of $(0.68) by 19.59 percent. This is a 97.73 percent increase over losses of $(24.19) per share
Benzinga Newsdesk
PRO
Camp4 Therapeutics Q2 EPS $(0.62) Down From $(0.11) YoY, Sales $1.497M Down From $61.714M YoY
Benzinga Newsdesk
